心血管疾病多基因风险评分:美国心脏协会科学声明
该科学声明由美国心脏协会发布,综述了心血管疾病多基因风险评分的当代科学、临床考量与未来挑战。声明聚焦冠状动脉疾病、高胆固醇血症、2型糖尿病、心房颤动和静脉血栓栓塞性疾病五种心血管代谢疾病及药物反应,为医疗人员、研究者、政策制定者和患者提供初步指导。
要点
- 多基因风险评分可用于五种心血管代谢疾病的风险评估。
- 遗传分析正广泛用于大型研究、生物样本库和直接面向消费者的检测。
- 临床 encounters 中患者和医生越来越多地面临多基因风险评分。
核心结论
- 多基因风险评分是心血管疾病风险预测的新兴工具,声明综述其科学、临床考量与未来挑战并提供初步指导。
研究设计与样本
- 美国心脏协会科学声明,综述当代科学、临床考量与未来挑战,聚焦五种心血管代谢疾病及药物反应。
主要发现
- 双胞胎和家族聚集研究表明多种心血管疾病在普通人群中具有遗传性。
- 全基因组关联研究持续阐明心血管疾病的因果机制。
- 心血管风险等位基因的系统编目促成了多基因风险评分的发展。
关键数值与推荐
- 声明选定了五种心血管代谢疾病:冠状动脉疾病、高胆固醇血症、2型糖尿病、心房颤动和静脉血栓栓塞性疾病。
- 声明还涉及对药物治疗的反应。
临床怎么用
- 医疗专业人员、研究者、政策制定者和患者可参考声明中的初步指导。
- 临床 encounters 中应准备应对患者的多基因风险评分信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cardiovascular disease is the leading contributor to years lost due to disability or premature death among adults. Current efforts focus on risk prediction and risk factor mitigation' which have been recognized for the past half-century. However, despite advances, risk prediction remains imprecise with persistently high rates of incident cardiovascular disease. Genetic characterization has been proposed as an approach to enable earlier and potentially tailored prevention. Rare mendelian pathogenic variants predisposing to cardiometabolic conditions have long been known to contribute to disease risk in some families. However, twin and familial aggregation studies imply that diverse cardiovascular conditions are heritable in the general population. Significant technological and methodological advances since the Human Genome Project are facilitating population-based comprehensive genetic profiling at decreasing costs. Genome-wide association studies from such endeavors continue to elucidate causal mechanisms for cardiovascular diseases. Systematic cataloging for cardiovascular risk alleles also enabled the development of polygenic risk scores. Genetic profiling is becoming widespread in large-scale research, including in health care-associated biobanks, randomized controlled trials, and direct-to-consumer profiling in tens of millions of people. Thus, individuals and their physicians are increasingly presented with polygenic risk scores for cardiovascular conditions in clinical encounters. In this scientific statement, we review the contemporary science, clinical considerations, and future challenges for polygenic risk scores for cardiovascular diseases. We selected 5 cardiometabolic diseases (coronary artery disease, hypercholesterolemia, type 2 diabetes, atrial fibrillation, and venous thromboembolic disease) and response to drug therapy and offer provisional guidance to health care professionals, researchers, policymakers, and patients.
引用
- O'Sullivan JW, Raghavan S, Marquez-Luna C, et al. Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2022. PMID: 35862132. doi:10.1161/CIR.0000000000001077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。